- Guide to PHARMACOLOGY
Synonyms: Vesicare® | YM-67905 | YM-905
solifenacin is an approved drug (FDA (2004), UK (2009))
Compound class: Synthetic organic
Comment: The marketed formulation contains solifenacin succinate (PubChem CID 216457).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: solifenacin
1. Ikeda K, Kobayashi S, Suzuki M, Miyata K, Takeuchi M, Yamada T, Honda K. (2002)
M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
Naunyn Schmiedebergs Arch Pharmacol, 366 (2): 97-103. [PMID:12122494]
2. Naito R, Yonetoku Y, Okamoto Y, Toyoshima A, Ikeda K, Takeuchi M. (2005)
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.
J Med Chem, 48 (21): 6597-606. [PMID:16220976]
3. Prat M, Buil MA, Fernández MD, Castro J, Monleón JM, Tort L, Casals G, Ferrer M, Huerta JM, Espinosa S et al.. (2011)
Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists.
Bioorg Med Chem Lett, 21 (11): 3457-61. [PMID:21524581]
4. Sinha S, Gupta S, Malhotra S, Krishna NS, Meru AV, Babu V, Bansal V, Garg M, Kumar N, Chugh A et al.. (2010)
AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.
Br J Pharmacol, 160 (5): 1119-27. [PMID:20590605]